eligibility_summary
Adults 18–75 with non‑squamous NSCLC (stage IIIB/C or IV), EGFR‑sensitizing mutation, no prior systemic therapy, ≥1 RECIST 1.1 target lesion, ECOG 0–1, life expectancy ≥12 weeks, adequate organs. Exclude mixed histology (>10% squamous/NE), prior TROP2 or topo‑I drugs, CNS/leptomeningeal disease, recent other cancers, major cardiac/ECG issues, ILD/pneumonitis, severe lung injury, unresolved AEs, immunosuppression, active TB/hepB/hepC/HIV/syphilis, prior allogeneic transplant, allergy to study drugs, recent live vaccines, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 first-line EGFR-mutant non-squamous NSCLC trial comparing SKB264 + osimertinib vs osimertinib alone. SKB264: TROP2-targeting antibody–drug conjugate (humanized mAb with a cleavable linker to a topoisomerase I inhibitor). Mechanism: binds TROP2 on tumor cells, internalizes, and releases the topo‑I payload to cause DNA damage and cell death (potential bystander effect). Osimertinib: third‑generation, irreversible small‑molecule EGFR tyrosine kinase inhibitor (80 mg QD) that blocks mutant EGFR (exon 19 del/L858R ± T790M), suppressing downstream MAPK and PI3K/AKT signaling. Targets/pathways: TROP2-expressing NSCLC cells and EGFR‑mutant tumor cells, EGFR/ERBB signaling and DNA replication/repair via topoisomerase I.